These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16429298)

  • 1. Apoptotic cell death in toxic epidermal necrolysis: the Fas ligand assumption.
    Gravante G; Esposito G; Filingeri V; Delogu D; Castrì F; Montone A
    Arch Dermatol Res; 2006 Mar; 297(9):430-1; author reply 432. PubMed ID: 16429298
    [No Abstract]   [Full Text] [Related]  

  • 2. [Epidermal necrolysis: mechanisms of keratinocyte apoptosis].
    Roujeau JC; Gélard K; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):188-91. PubMed ID: 16457761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
    Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
    Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidermic necrolysis: advances in pathogenesis].
    Roujeau JC
    Ann Dermatol Venereol; 2000 May; 127(5):546-7. PubMed ID: 10863193
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Marzano AV; Frezzolini A; Caproni M; Parodi A; Fanoni D; Quaglino P; Girgenti V; La Placa M; Fabbri P; Caputo R; Berti E
    Int J Immunopathol Pharmacol; 2007; 20(3):557-66. PubMed ID: 17880768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the potential role of cytokines in toxic epidermal necrolysis.
    Nassif A; Moslehi H; Le Gouvello S; Bagot M; Lyonnet L; Michel L; Boumsell L; Bensussan A; Roujeau JC
    J Invest Dermatol; 2004 Nov; 123(5):850-5. PubMed ID: 15482470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas (CD95)-related apoptosis and rheumatoid arthritis.
    Peng SL
    Rheumatology (Oxford); 2006 Jan; 45(1):26-30. PubMed ID: 16159946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytofluorometric analysis of chosen markers of apoptosis CD95/CD95L (Fas/FasL) in thyroid tissues from young patients with Graves' disease and Hashimoto's thyroiditis].
    Bossowski A; Stasiak-Barmuta A; Czarnocka B; Urban M; Łyczkowska A; Niedziela M; Bardadin K; Czerwińska J; Dadan J; Baltaziak M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(2):83-90. PubMed ID: 16813711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis.
    Viard-Leveugle I; Gaide O; Jankovic D; Feldmeyer L; Kerl K; Pickard C; Roques S; Friedmann PS; Contassot E; French LE
    J Invest Dermatol; 2013 Feb; 133(2):489-98. PubMed ID: 22992806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas (CD95/Apo-1)/Fas ligand expression in neonates with pontosubicular neuron necrosis.
    van Landeghem FK; Felderhoff-Mueser U; Moysich A; Stadelmann C; Obladen M; Brück W; Bührer C
    Pediatr Res; 2002 Feb; 51(2):129-35. PubMed ID: 11809905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure.
    Mita A; Hashikura Y; Tagawa Y; Nakayama J; Kawakubo M; Miyagawa S
    Am J Gastroenterol; 2005 Nov; 100(11):2551-9. PubMed ID: 16279913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underexpression and overexpression of Fas and Fas ligand: a double-edged sword.
    Randhawa SR; Chahine BG; Lowery-Nordberg M; Cotelingam JD; Casillas AM
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):286-92. PubMed ID: 20408337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Saeed HN; Chodosh J
    Semin Ophthalmol; 2016; 31(1-2):85-90. PubMed ID: 26959133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
    Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
    Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis dominant in the periinfarct area of human ischaemic stroke--a possible target of antiapoptotic treatments.
    Sairanen T; Karjalainen-Lindsberg ML; Paetau A; Ijäs P; Lindsberg PJ
    Brain; 2006 Jan; 129(Pt 1):189-99. PubMed ID: 16272167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Eginli A; Shah K; Watkins C; Krishnaswamy G
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):143-147. PubMed ID: 28153080
    [No Abstract]   [Full Text] [Related]  

  • 18. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
    Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD95 system counter attack and prognostic impact.
    Debatin KM
    Onkologie; 2006 Sep; 29(8-9):358-9. PubMed ID: 16974111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of apoptosis in the pathogenesis of dermatitis herpetiformis.
    Caproni M; Torchia D; Antiga E; Degl'Innocenti D; Barletta E; Baroni G; Santucci M; Fabbri P
    Int J Immunopathol Pharmacol; 2005; 18(4):691-9. PubMed ID: 16388717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.